IL DONG PHARMACEUTICAL CO., LTD. Q3 profit from main business KRW 7.1 billion on KRW 151.0 billion sales; net loss
AI summary · Not investment advice
Iljin...
Operating profit · 3 months
KRW 7.1 billion
Key facts
- Revenue (3 months)
- KRW 151.0 billion
- Net income (3 months)
- KRW -5.2 billion
- Period
- Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
- Revenue (prior-year 3 months)
- KRW 145.5 billion
- Revenue (year to date)
- KRW 440.8 billion
- Operating profit (prior-year 3 months)
- KRW 6.8 billion
- Operating profit (year to date)
- KRW 18.4 billion
- Net income (prior-year 3 months)
- KRW 21.5 billion
- Net income (year to date)
- KRW 7.2 billion
Commentary
AI commentary · Not investment advice
What happened
Ildong Pharmaceutical reported its consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 150.96 billion. That is 3.8% above the same 3 months a year earlier (KRW 145.46 billion) and 2.1% above the previous quarter.
In the company's terms
Operating profit (profit from the core business) for the 3 months was KRW 7.14 billion. That is 5.7% above the same period a year earlier (KRW 6.76 billion). It is 260.8% above the previous quarter.
What changes for shareholders
Net income (final profit after taxes and all other costs) for the 3 months was a loss of KRW 5.23 billion. A year earlier, the same 3 months showed net income of KRW 21.49 billion. The company swung to a loss from the previous quarter.
For the year to date, sales were KRW 440.82 billion. Operating profit was KRW 18.35 billion. Net income was KRW 7.25 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
I